Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Biosante Pharma Charts. Click Here for more Biosante Pharma Charts.](/p.php?pid=staticchart&s=A%5EBPA&p=8&t=15)
BioSante Pharmaceuticals, Inc. (Amex:BPA) today announced that
Stephen M. Simes, the Company's president and chief executive officer,
will present a corporate and clinical overview of the Company at the
UBS Global Life Sciences Conference, taking place at the Grand Hyatt
Hotel in New York City, on September 28, 2006.
Mr. Simes' presentation is scheduled for 2:30 p.m. EDT. A live
audio webcast of BioSante's presentation may be accessed at
http://www.biosantepharma.com/investors/events.html and a replay will
be available at the same link for 90 days.
About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to
treat both men and women. These hormone therapy products are gel
formulations for transdermal administration that deliver bioidentical
estradiol and testosterone. BioSante's lead products include
Bio-E-Gel(R) (transdermal estradiol gel) for the treatment of women
with menopausal symptoms, and LibiGel(R) (transdermal testosterone
gel) for the treatment of female sexual dysfunction (FSD). A Bio-E-Gel
new drug application (NDA) was submitted to the FDA in the first
quarter 2006. The current market in the U.S. for estrogen and
testosterone products is approximately $2.5 billion. The transdermal
gel formulations used in the women's gel products are licensed by
BioSante from Antares Pharma Inc. The company also is developing its
calcium phosphate nanotechnology (CaP) for novel vaccines, including
avian flu and biodefense vaccines for toxins such as anthrax and
ricin, and drug delivery systems. Additional information is available
online at: www.biosantepharma.com.
BioSante Pharmaceuticals, Inc. (Amex:BPA) today announced that Stephen
M. Simes, the Company's president and chief executive officer, will
present a corporate and clinical overview of the Company at the UBS
Global Life Sciences Conference, taking place at the Grand Hyatt Hotel
in New York City, on September 28, 2006.
Mr. Simes' presentation is scheduled for 2:30 p.m. EDT. A live audio
webcast of BioSante's presentation may be accessed at http://www.biosantepharma.com/investors/events.html
and a replay will be available at the same link for 90 days.
About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat
both men and women. These hormone therapy products are gel formulations
for transdermal administration that deliver bioidentical estradiol and
testosterone. BioSante's lead products include Bio-E-Gel(R) (transdermal
estradiol gel) for the treatment of women with menopausal symptoms, and
LibiGel(R) (transdermal testosterone gel) for the treatment of female
sexual dysfunction (FSD). A Bio-E-Gel new drug application (NDA) was
submitted to the FDA in the first quarter 2006. The current market in
the U.S. for estrogen and testosterone products is approximately $2.5
billion. The transdermal gel formulations used in the women's gel
products are licensed by BioSante from Antares Pharma Inc. The company
also is developing its calcium phosphate nanotechnology (CaP) for novel
vaccines, including avian flu and biodefense vaccines for toxins such as
anthrax and ricin, and drug delivery systems. Additional information is
available online at: www.biosantepharma.com.